Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report released on Saturday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

MRNS has been the topic of a number of other reports. TD Cowen restated a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Royal Bank of Canada cut their target price on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a research note on Friday, October 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $4.00 price target on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. Jefferies Financial Group reiterated a “hold” rating and issued a $0.50 price objective (down from $5.00) on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Finally, HC Wainwright restated a “neutral” rating and set a $2.00 target price on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $4.79.

Marinus Pharmaceuticals Trading Down 0.2 %

MRNS opened at $0.55 on Friday. The stock has a market capitalization of $30.32 million, a P/E ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a 12 month low of $0.22 and a 12 month high of $10.50. The firm’s fifty day simple moving average is $0.49 and its 200 day simple moving average is $0.85.

Institutional Trading of Marinus Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. World Investment Advisors LLC bought a new position in shares of Marinus Pharmaceuticals in the 3rd quarter valued at about $104,000. Virtu Financial LLC acquired a new stake in Marinus Pharmaceuticals in the 4th quarter valued at about $36,000. GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in Marinus Pharmaceuticals during the fourth quarter worth about $54,000. Jacobs Levy Equity Management Inc. increased its position in Marinus Pharmaceuticals by 39.5% during the third quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock worth $729,000 after buying an additional 117,255 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Marinus Pharmaceuticals by 1,968.5% in the third quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock valued at $234,000 after buying an additional 126,752 shares during the period. 98.80% of the stock is owned by institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.